Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline. The European Medicines ...

AstraZeneca and Daiichi Sankyo confirmed today that they have ... It's not clear yet if they will adopt the same go-to-market strategy in Europe. Preliminary results from TROPION-Lung05 reported ...

Head of Europe and Canada Oncology Business Division, Daiichi Sankyo. “Greater public understanding of breast cancer and metastatic breast cancer is needed to empower the European population to ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Revenue growth was fueled by oncology products, particularly ENHERTU, which retained leading market shares in the US, Europe ... Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab ... This global, randomised, open-label trial enrolled 494 subjects in Europe, South America, and Asia. The trial compared the safety ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...